C-type lectin domain family 12 member AGenealiases: CD371 · CLL-1 · CLL1 · DCAL-2 · MICL · hKLRL1
Q-omics provides the consensus-scored CLEC12A profile across patient tissues and cancer cell-line models. CLEC12A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLEC12A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CLEC12A RNA expression shows 15,768 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CLEC12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC12A survival associations across molecular data types. CLEC12A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC12A RNA expression–survival associations across cancer types. High CLEC12A expression shows unfavorable associations in UVM, but favorable associations in SKCM, LUAD, CESC, LIHC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CLEC12A RNA expression.
This table summarizes CLEC12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC12A shows lower tumor expression in LUAD, LUSC and LIHC and higher tumor expression in KIRC, HNSC and THCA. The KIRC box plot shows higher CLEC12A RNA expression in tumor versus normal tissue (log2 FC = +1.672, t-test p < 0.001).
This table shows molecular features associated with CLEC12A in patient tissues and cancer cell lines. In patient samples, CLEC12A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
